{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:10:11Z","timestamp":1791519011482,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40264-017-0576-4","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T15:01:53Z","timestamp":1501167713000},"page":"1231-1240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience"],"prefix":"10.1007","volume":"40","author":[{"given":"Helena","family":"Gama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Gra\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds M.","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"576_CR1","unstructured":"European Medicines Agency. Zebinix (eslicarbazepine acetate): EU summary of product characteristics. 2017. Available from: http:\/\/www.ema.europa.eu\/ema\/ . Accessed 15 July 2017."},{"key":"576_CR2","unstructured":"Sunovion Pharmaceuticals Inc. Aptiom\u00ae (eslicarbazepine acetate) tablets, for oral use: US prescribing information. 2015. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022416s001lbl.pdf . Accessed 15 July 2017."},{"issue":"3","key":"576_CR3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","volume":"50","author":"C Elger","year":"2009","unstructured":"Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50(3):454\u201363.","journal-title":"Epilepsia."},{"issue":"2\u20133","key":"576_CR4","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","volume":"89","author":"E Ben-Menachem","year":"2010","unstructured":"Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010;89(2\u20133):278\u201385.","journal-title":"Epilepsy Res"},{"issue":"5","key":"576_CR5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","volume":"120","author":"A Gil-Nagel","year":"2009","unstructured":"Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P. Efficacy and safety of 800 and 1200\u00a0mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009;120(5):281\u20137.","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"576_CR6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","volume":"56","author":"MR Sperling","year":"2015","unstructured":"Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Carlo A, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56(2):244\u201353.","journal-title":"Epilepsia."},{"issue":"1","key":"576_CR7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1528-1167.2012.03605.x","volume":"54","author":"A Gil-Nagel","year":"2013","unstructured":"Gil-Nagel A, Elger C, Ben-Menachem E, Halasz P, Lopes-Lima J, Gabbai AA, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia. 2013;54(1):98\u2013107.","journal-title":"Epilepsia."},{"key":"576_CR8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.yebeh.2017.04.019","volume":"72","author":"V Biton","year":"2017","unstructured":"Biton V, Rogin JB, Krauss G, Abou-Khalil B, Rocha JF, Moreira J, et al. Adjunctive eslicarbazepine acetate: a pooled analysis of three phase III trials. Epilepsy Behav. 2017;72:127\u201334.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"576_CR9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2012.03595.x","volume":"54","author":"T Nunes","year":"2013","unstructured":"Nunes T, Rocha JF, Falcao A, Almeida L, Soares-da-Silva P. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013;54(1):108\u201316.","journal-title":"Epilepsia."},{"issue":"8","key":"576_CR10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/epi.12242","volume":"54","author":"C Elger","year":"2013","unstructured":"Elger C, Bialer M, Falcao A, Vaz-da-Silva M, Nunes T, Almeida L, et al. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia. 2013;54(8):1453\u201361.","journal-title":"Epilepsia."},{"issue":"6","key":"576_CR11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","volume":"53","author":"M Bialer","year":"2012","unstructured":"Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935\u201346.","journal-title":"Epilepsia."},{"issue":"4","key":"576_CR12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00126839-200506040-00002","volume":"6","author":"J Maia","year":"2005","unstructured":"Maia J, Vaz-da-Silva M, Almeida L, Falc\u00e3o A, Silveira P, Guimar\u00e3es S, et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D. 2005;6(4):201\u20136.","journal-title":"Drugs R D."},{"issue":"Suppl. 1","key":"576_CR13","first-page":"106","volume":"13","author":"J Kharidia","year":"2013","unstructured":"Kharidia J, Blum D, Cheng H. A pharmacokinetic study comparing eslicarbazepine acetate administered orally as crushed or intact tablet in healthy volunteers. Epilepsy Curr. 2013;13(Suppl. 1):106.","journal-title":"Epilepsy Curr."},{"issue":"3","key":"576_CR14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eplepsyres.2013.02.020","volume":"105","author":"A Falcao","year":"2013","unstructured":"Falcao A, Vaz-da-Silva M, Gama H, Nunes T, Almeida L, Soares-da-Silva P. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol\/levonorgestrel oral contraceptive in healthy women. Epilepsy Res. 2013;105(3):368\u201376.","journal-title":"Epilepsy Res"},{"key":"576_CR15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2015.03.006","volume":"28","author":"A Reimers","year":"2015","unstructured":"Reimers A, Brodtkorb E, Sabers A. Interactions between hormonal contraception and antiepileptic drugs: clinical and mechanistic considerations. Seizure. 2015;28:66\u201370.","journal-title":"Seizure."},{"issue":"1\u20132","key":"576_CR16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eplepsyres.2013.04.009","volume":"106","author":"A Falcao","year":"2013","unstructured":"Falcao A, Pinto R, Nunes T, Soares-da-Silva P. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res. 2013;106(1\u20132):244\u20139.","journal-title":"Epilepsy Res"},{"issue":"1","key":"576_CR17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","volume":"4","author":"L Almeida","year":"2007","unstructured":"Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics. 2007;4(1):88\u201396.","journal-title":"Neurotherapeutics."},{"issue":"5","key":"576_CR18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1528-1157.2001.43600.x","volume":"42","author":"MJ Bonifacio","year":"2001","unstructured":"Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia. 2001;42(5):600\u20138.","journal-title":"Epilepsia."},{"key":"576_CR19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","volume":"89","author":"S Hebeisen","year":"2015","unstructured":"Hebeisen S, Pires N, Loureiro AI, Bonifacio MJ, Palma N, Whyment A, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015;89:122\u201335.","journal-title":"Neuropharmacology"},{"issue":"Suppl. 1","key":"576_CR20","first-page":"414","volume":"13","author":"S Hebeisen","year":"2012","unstructured":"Hebeisen S, Soares-da-Silva P. Slow and fast inactivation of voltage-gated sodium channels by eslicarbazepine, carbamazepine, oxcarbazepine and lacosamide. Epilepsy Curr. 2012;13(Suppl. 1):414\u20135.","journal-title":"Epilepsy Curr."},{"issue":"Suppl. 6","key":"576_CR21","first-page":"260","volume":"52","author":"K Brady","year":"2011","unstructured":"Brady K, Hebeisen S, Konrad D, Soares-da-Silva P. The effects of eslicarbazepine, R-licarbazepine, oxcarbazepine and carbamazepine on ion transmission Cav3.2 channels. Epilepsia. 2011;52(Suppl. 6):260.","journal-title":"Epilepsia."},{"issue":"1","key":"576_CR22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11596290-000000000-00000","volume":"26","author":"A Falcao","year":"2012","unstructured":"Falcao A, Fuseau E, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses. CNS Drugs. 2012;26(1):79\u201391.","journal-title":"CNS Drugs"},{"key":"576_CR23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/epi.12774","volume":"55","author":"R Costa","year":"2014","unstructured":"Costa R, Oliveira C, Lopes N, Gama H, Sousa R, Nunes T, et al. Safety and efficacy of eslicarbazepine acetate treatment in elderly patients. Epilepsia. 2014;55:112.","journal-title":"Epilepsia."},{"key":"576_CR24","unstructured":"Bial\u2013Portela & C\u00aa, S.A. Data on file; 2015."},{"issue":"7","key":"576_CR25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","volume":"22","author":"G Zaccara","year":"2013","unstructured":"Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A. Neurological adverse events of new generation sodium blocker antiepileptic drugs: meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013;22(7):528\u201336.","journal-title":"Seizure."},{"key":"576_CR26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/0091270007305480","volume":"47","author":"L Almeida","year":"2007","unstructured":"Almeida L, Potgieter JH, Maia J, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with renal impairment. J Clin Pharmacol. 2007;47:1183\u2013211.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"576_CR27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","volume":"64","author":"L Almeida","year":"2008","unstructured":"Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64(3):267\u201373.","journal-title":"Eur J Clin Pharmacol"},{"key":"576_CR28","doi-asserted-by":"crossref","unstructured":"Stephen LJ, Wishart A, Brodie MJ. Psychiatric side effects and antiepileptic drugs: observations from prospective audits. Epilepsy Behav. 2017;71(Pt A):73\u20138.","DOI":"10.1016\/j.yebeh.2017.04.003"},{"issue":"3","key":"576_CR29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00415-016-8338-2","volume":"264","author":"SD Shorvon","year":"2017","unstructured":"Shorvon SD, Trinka E, Steinhoff BJ, Holtkamp M, Villanueva VJP, et al. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies. J Neurol. 2017;264(3):421\u201331.","journal-title":"J Neurol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0576-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0576-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0576-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T18:47:40Z","timestamp":1692902860000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0576-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["576"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0576-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,27]]}}}